Anti-HIV regimens on trial in ACTG 384 study

The AIDS Clinical Trials Group (ACTG) 384 study compared six regimens containing the nucleoside reverse transcriptase inhibitor (NRTI) backbones of zidovudine plus lamivudine or stavudine plus didanosine, in combination with the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz and/or the protease inhibitor (PI) nelfinavir in treatment-naïve patients with HIV infections. Interim results presented at the XIV International AIDS Conference [Barcelona, Spain; July 2002] showed that none of the regimens was significantly more effective than the others with respect to the study's primary endpoint. However, the combination of efavirenz plus lamivudine and zidovudine was the most effective with respect to the time to failure of the first-line regimen, a secondary endpoint of the study.